护肾Ⅰ号延缓慢性肾衰临床观察  

Clinical Efficacy of Hushen Ⅰ Formula Delaying Chronic Renal Failure

作　　者：周奕岑 彭静微 ZHOU Yicen;PENG Jingwei(Zhangjiagang Hospital,Nanjing University of Traditional Chinese Medicine,Zhangjiagang 215600,Jiangsu,China;Zhangjiagang Hospital,Suzhou University,Zhangjiagang 215600,Jiangsu,China)

机构地区：[1]南京中医药大学附属张家港医院,江苏张家港215600 [2]苏州大学附属张家港医院,江苏张家港215600

出　　处：《实用中医内科杂志》2021年第12期37-40,共4页Journal of Practical Traditional Chinese Internal Medicine

基　　金：江苏省自然科学基金(BK20180996)。

摘　　要：目的探讨护肾Ⅰ号对慢性肾脏病3-4期患者的临床疗效。方法选取2019年1月—2020年12月收入张家港市中医医院的慢性肾脏病3-4期患者100例为研究对象。根据治疗方法的不同分为研究组(52例)与对照组(48例),对照组给予常规西药治疗,研究组在对照组基础上给予护肾Ⅰ号治疗。观察两组患者治疗效果、肾功能指标及不良反应。结果研究组治疗总有效率96.15%高于对照组83.33%(P<0.05)。治疗后,两组患者BUN、Scr、NGAL、ACR、β2-MG及24hPRO水平均降低,且研究组低于对照组(P<0.05)。治疗后,两组患者IL-6、CRP水平均降低,且研究组低于对照组(P<0.05)。治疗后,研究组与对照组收缩压、舒张压、Ca及P等指标均较前改善,且研究组优于对照组(P<0.05)。研究组腹泻、皮疹、恶心呕吐及肝功能异常等不良反应发生率与对照组比较无意义(P>0.05)。结论护肾Ⅰ号治疗慢性肾脏病3-4期患者疗效确切,能显著改善肾功能并控制炎症,纠正钙磷代谢紊乱,对延缓慢性肾衰具有一定作用,且不良反应较少,值得临床应用推广。Objective To investigate the clinical efficacy of Hushen Ⅰ Formula on chronic kidney disease in patients of stage 3-4. Methods One hundred patients with chronic kidney disease in stage 3-4 admitted to the Zhangjiagang Hospital of Traditional Chinese Medicine from January 2019 to December 2020 were selected and randomly divided into study group(52 cases) and control group(48 cases). The control group received conventional western medicine treatment, and the study group received Hushen Ⅰ Formulaon the basis of the control group. The efficacy, renal function indicators and adverse reactionswere recorded. Results The total effective rate of treatment in the study group was higher than that in the control group(96.15% vs. 83.33%, P<0.05). After treatment, the levels of BUN, Scr, NGAL, ACR, β2-MG and 24 hPRO of the two groups were decreased, and those of the study group were lower than those of the control group(P<0.05). After treatment, the levels of IL-6 and CRP of the two groups were decreased, and those of the study group were lower than those of the control group(P<0.05). After treatment, systolic blood pressure, diastolic blood pressure andlevels of Ca and P were improved compared with the previous ones in both groups, and those of the study group were better than those of the control group(P<0.05). The incidence of adverse reactions such as diarrhea, skin rash, nausea and vomiting and abnormal liver function in the study group was not significant compared with that in the control group(P>0.05). Conclusions Hushen Ⅰ Formula has definite efficacy on chronic kidney disease in stage 3-4. It can significantly improve renal function and renal anemia, correct calcium and phosphorus metabolism disorders, and has a certain effect on delaying chronic renal failure with less adverse reactions. It is worthy of clinical application and promotion.

关 键 词：慢性肾脏病 护肾Ⅰ号 延缓 临床观察 

分 类 号：R692.5[医药卫生—泌尿科学]